A retrospective study evaluating efficacy and safety of compassionate use of tocilizumab in 13 patients with severe-to-critically ill COVID-19: analysis of well-responding cases and rapidly-worsening cases after tocilizumab administration

Shoji Hashimoto¹*, Heita Kitajima¹*, Tsuyoshi Arai¹, Yoshitaka Tamura¹, Takayuki Nagai¹, Hiroshi Morishita¹, Hiroto Matsuoka¹, Yuki Han¹, Seijiro Minamoto¹, Tomonori Hirasima¹, Tomoki Yamada¹, Yozo Kashiwa¹, Makoto Kameda¹, Seiji Yamaguchi¹, Kazuko Uno², Emi Nakayama², Tatsuo Shioda³, Kazuyuki Yoshizaki⁴, Sujin Kang⁵, Tadamitsu Kishimoto⁵, Toshio Tanaka¹

¹Osaka Prefecture Hospital Organization Osaka Habikino Medical Center, Osaka 583-3588, Japan
²Louis Pasteur Center for Medical Research, Kyoto 606-8225, Japan
³Department of Viral Infection, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan
⁴Institute of Scientific and Industry Research, Osaka University, Osaka 565-0871, Japan
⁵Laboratory of Immune Regulation, Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan

Correspondence to: Toshio Tanaka MD, Ph.D. Osaka Prefectural Hospital Organization Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka 583-8588, Japan
mail: ttanak@ra.opho.jp

*These authors contributed equally to this work.
Abstract
We administered tocilizumab into 13 severe-to-critically ill patients with coronavirus disease 2019 (COVID-19) for compassionate use in combination with potential anti-viral agents in those who required an oxygen supply and showed increased laboratory inflammatory markers such as C-reactive protein (CRP) and ferritin. One injection of tocilizumab led to rapid improvements in clinical features, inflammatory findings, and oxygen supply in seven patients with severe COVID-19 and substantial amelioration in two patients who were critically ill, whereas four patients, who exhibited rapidly worsened respiratory function, required artificial ventilatory support even after tocilizumab treatment. Three of these four patients ultimately recovered from deterioration after methylprednisolone treatment. Administration of tocilizumab did not affect viral elimination nor IgG production specific for the virus. Compared with well-responding patients, rapidly-worsened patients showed a significantly higher ratio of ferritin vs. CRP. These findings suggest that tocilizumab has beneficial effects in severe-to-critically ill patients with COVID-19; however, in some cases, addition of methylprednisolone is required for disease rescue.

Introduction
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndromes coronavirus-2 (SARS-CoV-2), has rapidly spread worldwide.1-4 By the end of May 2020, more than 6 million people were diagnosed with COVID-19, with a mortality rate of approximately 6%. Thus, vaccines and therapeutic drugs are urgently needed to stop the spread of the disease and decrease mortality; however, no vaccines and drugs except for
remdesivir as an emergency use drug have been developed and approved. Various studies have indicated that a cytokine storm, also known as hyperinflammation, is a pathological mechanism underlying the development of severe disease, leading to a critically ill state of patients including acute respiratory distress syndrome, multiple organ dysfunction syndrome, and shock. Among the cytokines involved in severe and critical cases of COVID-19, interleukin (IL)-6 is highly elevated and can be used a prognostic marker. Additionally, IL-6 plays a major pathological role in disease worsening. Several case series and case reports have demonstrated the beneficial effects of tocilizumab, a humanized anti-IL-6 receptor monoclonal antibody, in patients with COVID-19. Based on recent findings regarding the clinical and laboratory features of COVID-19, our hospital developed a therapeutic protocol for managing COVID-19 and used tocilizumab to treat severe-to-critically ill patients with COVID-19. Here, we report our experience using tocilizumab to treat patients with COVID-19.

**Patients and methods**

**Patients with COVID-19**

Seventy patients with COVID-19 were admitted to our hospital by the end of May 2020. Among them, 13 patients were diagnosed as severe-to-critically ill, as they required oxygen supply because of severe pneumonia and were intravenously administered tocilizumab at 400 mg once in combination with anti-SARS-CoV-2 drugs such as lopinavir/ritonavir, ciclesonide, or favipiravir. All patients provided written informed consent, and the off-label compassionate use of tocilizumab was approved by the Ethics Committee of Osaka Habikino Medical Center (Approved ID: 150-7).
Protocol of the indication of tocilizumab for patients with COVID-19

Based on various previous reports of characterizations patients with COVID-19, the inclusion criteria of off-label indication of tocilizumab were set as follows:

1. Elevated inflammatory findings: C-reactive protein (CRP) level >5 mg/dL or ferritin >1000 ng/mL
2. Requirement of oxygen supply or rapid progression according to chest image evaluation (more than 50% increase in infiltrates over 24-48 hours)

Patients with elevated procalcitonin and patients who also had bacterial infections were excluded.

Quantification of viral RNA

Viral RNA was isolated from 70 µL of serum using a QIAmp Viral RNA Mini kit (Qiagen), according to the manufacturers’ protocol. Viral RNA was quantified using a One-StepPrimeScript III RT-PCR kit (TaKaRa), and the following universal primers for N2 region of SARS-CoV-2: NIID_2019-nCOV_N_F2 AAATTTGGGGACCAGGAAC and NIID_2019-nCOV_N_R2 TGGCAGCTGTGTAGGTCAC with NIID_2019-nCOV_N_P2 probe: FAM-ATGTCGCGCATGGCATGGA-TAMRA. Five µL of extracted RNA was used for the reaction. The PCR conditions were 25°C for 10 min for activation, 52°C for 5 min for reverse transcription, 95°C 10 sec for inactivation, followed by 45 cycles of 95°C for 5 s, and 20°C for 30 s. The fluorescent signals were detected with a QuantiStudio 3 Real-Time PCR System (Applied Biosystems).

Detection of specific antibody against SARS-CoV-2
The serum levels of IgM and IgG class antibodies specific for SARS-CoV-2 were determined by using the Corona Virus COVID-19 Antibody Rapid Detection kit according to the manufacturer’s instructions (Healgen Scientific Ltd.). \(^1\) The test samples in an individual patient included all of the sera collected before and 1-2 and 3-4 weeks after tocilizumab injection, or in some cases at 4-5 weeks after injection, depending on the availability.

**Statistical analysis**

The significance of the difference between well-responding group and rapidly-worsening group was evaluated using the Man-Whitney U test. A value of \( P < 0.05 \) was considered as statistically significant.

**Results**

**Clinical outcome of tocilizumab administration**

The patients’ characteristic features and clinical courses are shown in Table 1. Eleven male patients and two female patients with a mean age of 63 years were evaluated. Five patients were complicated with diabetes mellitus, five with hypertension, and two with chronic obstructive pulmonary disease. At admission, two patients were critically ill and required artificial ventilator management before tocilizumab injection, and severe disease was diagnosed in 11 patients. The clinical course of each patient is shown in Table 1. Tocilizumab caused no adverse events. Seven patients promptly recovered from fever and malaise and lowered their oxygen support, and were free of oxygen support within a week on average (well-responding group). PCR analysis of the nasopharyngeal specimens showed negative results for SARS-CoV-2 10-25 days (15.4 days as average) and the
patients were discharged 12-27 days (17 days as average) after tocilizumab administration. However, four patients showed further worsening of respiratory function and required artificial ventilatory support (rapidly-worsening group); these patients were administered methylprednisolone and recovered from such a support within a week. Two patients were discharged from the hospital, and one patient died because of sudden laryngotracheal stenosis. Two patients who were critically ill and required artificial ventilator management before tocilizumab injection were ameliorated in respiratory function. Analysis of clinical outcomes showed that by 1 week after tocilizumab treatment, eight (62%), 1 (8%), and 4 (31%) patients improved, had no change, and worsened, respectively, whereas nine (69%), 3 (23%), and 1 patient (8%) were cured, improved, and died, respectively, by 1 month after treatment. A representative case that responded well to tocilizumab and a case that worsened despite tocilizumab injection are shown in Figures 1 and 2, respectively. The changes in laboratory parameters are shown in Figure 3. Tocilizumab injection rapidly decreased serum CRP levels followed by a gradual decrease in ferritin and increase in the number of peripheral lymphocytes.

**Difference between well-responding group and rapidly-worsening group**

Respiratory disturbance acutely progressed in some patients with severe disease. The clear difference in the clinical features between the well-responding group and the rapidly-worsening group was not observed. In the laboratory results, there was no difference in the basal levels of CRP and ferritin or in number of peripheral lymphocytes between groups, whereas the ratio of ferritin/CRP was significantly higher in the rapidly-worsening group than in the well-responding group (373.1 ± 346.8 vs. 83.7 ± 56.7, p = 0.01) (Table 2).
Effect of tocilizumab injection on viral elimination and antibody production

Because IL-6 plays a crucial role in the host defense against pathogens and promotes T cell and B cell activation and differentiation,\textsuperscript{18,19} we next evaluated whether tocilizumab injection affects elimination of SARS-CoV-2 and specific antibody production. Three out of nine patients tested showed viremia, and their viral load transiently increased at 2-3 days after tocilizumab injection but then decreased (Figure 4). In addition, we detected IgG class antibody in all nine patients, whose sera were available for the test at 1-2 weeks after tocilizumab administration. These results suggest that tocilizumab in combination with anti-viral drugs did not suppress viral elimination or induction of the IgG class antibody specific for SARS-CoV-2.

Discussion

We describe our experience in which tocilizumab was administered to 13 severe-to-critically ill patients with COVID-19. Seven patients promptly improved in response to tocilizumab (well-responding group), whereas four patients showed worsened respiratory function and required artificial ventilation (rapidly-worsening group). Recent various case series and case reports have demonstrated the promising efficacy of tocilizumab for severe-to-critically ill COVID-19 either monotherapy or its combination with corticosteroids,\textsuperscript{12-16,20-23} although opposite results were observed in some other studies.\textsuperscript{24,25} According to our experience with 13 patients with COVID-19 patients, it is due to the clinical status and the timing of tocilizumab administration.

Compared with patients with non-severe COVID-19, those with severe-to-
critically ill COVID-19 showed lymphocytopenia, elevated CRP, ferritin and D-dimer.\textsuperscript{6,7,11,26} Patients in the rapidly-worsening group showed a significantly higher ratio of ferritin/CRP, perhaps reflecting a more severe cytokine storm. CRP is predominantly regulated by IL-6; tocilizumab, as previously demonstrated in rheumatoid arthritis and Castleman disease;\textsuperscript{27} caused a prompt reduction in CRP levels in all patients with COVID-19 and a gradual reduction in ferritin levels along with an increase in the number of peripheral lymphocytes. Ferritin production is regulated by proinflammatory cytokines and IL-18;\textsuperscript{28} and thus high elevation of ferritin indicates exaggerated production of other cytokines in addition to IL-6. Similar effects occur in macrophage activation syndrome (MAS) complicated with systemic juvenile idiopathic arthritis (sJIA) and secondary haemophagocytic lymphohistiocytosis;\textsuperscript{6,18,29} in which ferritin is highly elevated, associated with the storm of various cytokines, including IL-1, IL-2, IL-6, IL-18, and IFN-\textgamma, and others. Although the incidence of MAS in patients with sJIA appears to be lower during tocilizumab treatment, tocilizumab does not completely suppress the onset of the condition. In such cases, prednisolone and cyclosporine are generally used. Similar to this situation, four patients in the rapidly-worsening group were administered methylprednisolone and recovered from artificial ventilatory support. Thus, as immunosuppressive therapeutic treatments, tocilizumab monotherapy or its combination with methylprednisolone may depend on the patient’s immunological status, and the ratio of ferritin/CRP may be a useful marker for selecting the treatment procedure, although additional studies are essential to confirm this.

IL-6 is a cytokine that helps maintain homeostasis. When infections occur, IL-6 is promptly produced and plays a major role against infectious agents by producing acute phase proteins and activating T cells and B cells, leading to their differentiation into
effector T cells and Ig production, respectively.\textsuperscript{18,19} Therefore, an important concern is that tocilizumab may suppress viral elimination and humoral immunity for the virus. However, our experience suggests that this is not the case when tocilizumab is administered with potential anti-viral drugs. Rather, flow cytometric analysis of immune cells from patients with COVID-19 showed that impaired immune cell cytotoxicity in severe cases was IL-6-dependent and thus targeting IL-6 may restore anti-viral activity.\textsuperscript{30}

This report has several limitations. The sample size was small, and the data were analyzed retrospectively. Moreover, the treatment protocol involved combination therapy of tocilizumab with anti-viral drugs, so the direct effect of tocilizumab could not be evaluated. Further evaluation using a randomized controlled trial design is essential.

Reference


https://doi.org/10.1093/ofid/ofaa105.


Figure 1. One representative case that responded well to tocilizumab administration

<table>
<thead>
<tr>
<th>Day</th>
<th>Symptoms</th>
<th>Oxygen inhalation</th>
<th>CRP (mg/dL)</th>
<th>Lymphocyte ( /mL)</th>
<th>Ferritin (ng/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 1</td>
<td>Headache</td>
<td>3L</td>
<td>13.51</td>
<td>530</td>
<td>1522.6</td>
</tr>
<tr>
<td>Day 5</td>
<td></td>
<td>5L</td>
<td>1.07</td>
<td>1150</td>
<td>889.4</td>
</tr>
<tr>
<td>Day 7</td>
<td></td>
<td>2L</td>
<td>0.10</td>
<td>1580</td>
<td>652.9</td>
</tr>
<tr>
<td>Day 34</td>
<td></td>
<td>1L</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Case 2
Figure 2. One representative case that worsened rapidly after tocilizumab administration.

**Case 10**

**Day 25 Discharge**

Day 2-11 in other hospital

<table>
<thead>
<tr>
<th>Medication</th>
<th>Day 1</th>
<th>Day 7</th>
<th>Day 12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tocilizumab</td>
<td>5.06</td>
<td>0.02</td>
<td>0.01</td>
</tr>
<tr>
<td>Ciclesonide</td>
<td>438</td>
<td>288</td>
<td>1209</td>
</tr>
<tr>
<td>Favipiravir</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Methylprednisolone</td>
<td>1208.9</td>
<td>NA</td>
<td>319.9</td>
</tr>
</tbody>
</table>

Oxygen inhalation (/min)

- SL
- 3L
- Under artificial ventilation

**Notes:**
- CRP (mg/dL)
- Lymphocyte (/mL)
- Ferritin (ng/mL)

**Images:**

- Day 1
- Day 7
- Day 12
Figure 3. Changes in CRP, ferritin, and the number of peripheral lymphocytes before and after tocilizumab injection

The dotted line represents the data from the rapidly-worsening group.
Figure 4. Changes in SARS-CoV-2 load before and after tocilizumab injection

The dotted line represents the data from the rapidly-worsening group.
Table 1. Characteristic features and clinical course of patients with COVID-19 treated with tocilizumab

<table>
<thead>
<tr>
<th>Case</th>
<th>Age (years) /Gender</th>
<th>Complications</th>
<th>Anti-viral drugs combined with TCZ</th>
<th>Requiring O₂ conc. and laboratory findings before TCZ injection</th>
<th>Clinical course after TCZ injection</th>
<th>Outcome at 1 month</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>72/M</td>
<td>NTM, COPD, Lower pharyngeal cancer</td>
<td>F+C</td>
<td>O₂ 3.6 L/min, Lym 175, CRP 8.62, Ferritin 153.1</td>
<td>Day 5: CRP 0.54, Lym 450</td>
<td>Cure</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Day 8: O₂ 2L/min, CRP 0.14, Lym 610</td>
<td>Day 21: CRP 0.05, Lym 970, Ferritin 77.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Day 25: SARS-CoV-2 (-)</td>
<td>Day 29: Discharge with HOT</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>41/M</td>
<td></td>
<td>F+C</td>
<td>O₂ 3.5 L/min, Lym 330, CRP 13.51, Ferritin 1522.6</td>
<td>Day 5: O₂-free, CRP 1.07, Lym 1150, Ferritin 889.4</td>
<td>Cure</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Day 13: CRP 0.10, Lym 1580, Ferritin 652.9, SARS-CoV-2 (-)</td>
<td>Day 13: Discharge</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>63/M</td>
<td>HT</td>
<td>F+C</td>
<td>O₂ 3.5 L/min, Lym 1280, CRP 11.53, Ferritin 1531.8</td>
<td>Day 4: CRP 1.98, Lym 990, Ferritin 943.9</td>
<td>Cure</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Day 7: O₂-free, CRP 0.12, Lym 1664, Ferritin 592.5, SARS-CoV-2 (-)</td>
<td>Day 15: Discharge</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>68/M</td>
<td>DM</td>
<td>F+C</td>
<td>O₂ 2.6 L/min, Lym 999, CRP 3.93, Ferritin 681.1</td>
<td>Day 5: CRP 0.52, Lym 1036, Ferritin 880.6</td>
<td>Cure</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Day 6: O₂-free, CRP 0.17, Lym 1400, Ferritin 828.5, SARS-CoV-2 (-)</td>
<td>Day 13: Discharge</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>63/F</td>
<td>DM</td>
<td>F+C</td>
<td>O₂ 3.6 L/min, Lym 1130, CRP 7.01, Ferritin 334.3</td>
<td>Day 5: CRP 0.25, Lym 870, Ferritin 239.0</td>
<td>Cure</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Day 8: O₂-free, CRP 0.04, Lym 1376, Ferritin 241.8, SARS-CoV-2 (-)</td>
<td>Day 13: Discharge</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>79/M</td>
<td>DM HT COPD</td>
<td>L/R+C</td>
<td>Under artificial ventilation (FiO₂ 0.25-0.45), Lym 640, CRP 8.92, Ferritin 1238.9</td>
<td>Day 5: CRP 1.16, Lym 640</td>
<td>Improvement</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Day 8: CRP 0.26, Lym 1880</td>
<td>Day 11: Extubation</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Day 13: CRP 0.26, Lym 1140</td>
<td>Day 14: Re-intubation</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Day 19: SARS-CoV-2 (-)</td>
<td>Day 20: Tracheostomy</td>
<td></td>
</tr>
</tbody>
</table>

HOT: Hospital of Transthoracic emergencies, SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus-2.
<table>
<thead>
<tr>
<th>No.</th>
<th>Age/Sex</th>
<th>Comorbidities</th>
<th>Ventilation</th>
<th>Day 32: Re-extubation</th>
<th>Day 5: CRP 1.13, Lym 1010</th>
<th>Day 12: under artificial ventilation (FiO₂ 0.3)</th>
<th>Day 25: SARS-CoV-2 (-)</th>
<th>Improvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>71/M</td>
<td>DM, DM</td>
<td>L/R+C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Day 32: Re-extubation</td>
<td>O₂ 2-3 L/min</td>
<td>Day 5: CRP 1.13, Lym 1010</td>
<td>Day 12: under artificial ventilation (FiO₂ 0.3)</td>
<td>Day 25: SARS-CoV-2 (-)</td>
</tr>
<tr>
<td>8</td>
<td>79/M</td>
<td>F+C</td>
<td></td>
<td>Under artificial ventilation (FiO₂ 0.35-0.8), Lym 2130, CRP 7.47, Ferritin 4383.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>48/M</td>
<td>DM, DM, DM</td>
<td>F+C</td>
<td>O₂ 2-5 L/min, Lym 860, CRP 3.85, Ferritin 1110.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>62/F</td>
<td>RA, RA, DM</td>
<td>F+C</td>
<td>O₂ 3-5 L/min, CRP 5.06, Lym 438, Ferritin 1208.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>43/M</td>
<td>HT, HT</td>
<td>F+C</td>
<td>O₂ 2 L/min, CRP 9.28, Lym 1129, Ferritin 552.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>81/M</td>
<td>DM</td>
<td>mPSL pulse</td>
<td>O₂ 2-15 L/min, CRP 15.26, Lym 600, Ferritin 638.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>55/M</td>
<td>F+C</td>
<td></td>
<td>O₂ 2-3 L/min, CRP 6.77, Lym 665, Ferritin 1599.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Day 1:** Intubation and transfer to other hospital

**Day 2:** Intubation

**Day 5:** CRP 1.13, Lym 1010

**Day 12:** Under artificial ventilation (FiO₂ 0.3)

**Day 25:** SARS-CoV-2 (-)

**Day 32:** Re-extubation, O₂ 2-3 L/min

**Day 5:** CRP 1.13, Lym 1010

**Day 12:** Under artificial ventilation (FiO₂ 0.3)

**Day 25:** SARS-CoV-2 (-)

**Day 33:** Discharge

**Day 1:** Intubation and transfer to other hospital

**Day 2:** Intubation

**Day 5:** CRP 1.13, Lym 1010

**Day 12:** Under artificial ventilation (FiO₂ 0.3)

**Day 25:** SARS-CoV-2 (-)

**Day 32:** Re-extubation, O₂ 2-3 L/min

**Day 5:** CRP 1.13, Lym 1010

**Day 12:** Under artificial ventilation (FiO₂ 0.3)

**Day 25:** SARS-CoV-2 (-)

**Day 33:** Discharge

**Day 1:** Intubation and transfer to other hospital

**Day 2:** Intubation

**Day 5:** CRP 1.13, Lym 1010

**Day 12:** Under artificial ventilation (FiO₂ 0.3)

**Day 25:** SARS-CoV-2 (-)

**Day 32:** Re-extubation, O₂ 2-3 L/min

**Day 5:** CRP 1.13, Lym 1010

**Day 12:** Under artificial ventilation (FiO₂ 0.3)

**Day 25:** SARS-CoV-2 (-)

**Day 33:** Discharge

**Day 1:** Intubation and transfer to other hospital

**Day 2:** Intubation

**Day 5:** CRP 1.13, Lym 1010

**Day 12:** Under artificial ventilation (FiO₂ 0.3)

**Day 25:** SARS-CoV-2 (-)

**Day 32:** Re-extubation, O₂ 2-3 L/min

**Day 5:** CRP 1.13, Lym 1010

**Day 12:** Under artificial ventilation (FiO₂ 0.3)

**Day 25:** SARS-CoV-2 (-)

**Day 33:** Discharge

**Day 1:** Intubation and transfer to other hospital

**Day 2:** Intubation

**Day 5:** CRP 1.13, Lym 1010

**Day 12:** Under artificial ventilation (FiO₂ 0.3)

**Day 25:** SARS-CoV-2 (-)

**Day 32:** Re-extubation, O₂ 2-3 L/min

**Day 5:** CRP 1.13, Lym 1010

**Day 12:** Under artificial ventilation (FiO₂ 0.3)

**Day 25:** SARS-CoV-2 (-)

**Day 33:** Discharge

**Day 1:** Intubation and transfer to other hospital

**Day 2:** Intubation

**Day 5:** CRP 1.13, Lym 1010

**Day 12:** Under artificial ventilation (FiO₂ 0.3)

**Day 25:** SARS-CoV-2 (-)

**Day 32:** Re-extubation, O₂ 2-3 L/min

**Day 5:** CRP 1.13, Lym 1010

**Day 12:** Under artificial ventilation (FiO₂ 0.3)

**Day 25:** SARS-CoV-2 (-)

**Day 33:** Discharge

**Day 1:** Intubation and transfer to other hospital

**Day 2:** Intubation

**Day 5:** CRP 1.13, Lym 1010

**Day 12:** Under artificial ventilation (FiO₂ 0.3)

**Day 25:** SARS-CoV-2 (-)

**Day 32:** Re-extubation, O₂ 2-3 L/min

**Day 5:** CRP 1.13, Lym 1010

**Day 12:** Under artificial ventilation (FiO₂ 0.3)

**Day 25:** SARS-CoV-2 (-)

**Day 33:** Discharge

**Day 1:** Intubation and transfer to other hospital

**Day 2:** Intubation

**Day 5:** CRP 1.13, Lym 1010

**Day 12:** Under artificial ventilation (FiO₂ 0.3)

**Day 25:** SARS-CoV-2 (-)

**Day 32:** Re-extubation, O₂ 2-3 L/min

**Day 5:** CRP 1.13, Lym 1010

**Day 12:** Under artificial ventilation (FiO₂ 0.3)

**Day 25:** SARS-CoV-2 (-)

**Day 33:** Discharge

**Day 1:** Intubation and transfer to other hospital

**Day 2:** Intubation

**Day 5:** CRP 1.13, Lym 1010

**Day 12:** Under artificial ventilation (FiO₂ 0.3)

**Day 25:** SARS-CoV-2 (-)

**Day 32:** Re-extubation, O₂ 2-3 L/min

**Day 5:** CRP 1.13, Lym 1010

**Day 12:** Under artificial ventilation (FiO₂ 0.3)

**Day 25:** SARS-CoV-2 (-)

**Day 33:** Discharge

**Day 1:** Intubation and transfer to other hospital

**Day 2:** Intubation

**Day 5:** CRP 1.13, Lym 1010

**Day 12:** Under artificial ventilation (FiO₂ 0.3)

**Day 25:** SARS-CoV-2 (-)
TCZ: tocilizumab; NTM: non-tuberculous mycobacteriosis; COPD: chronic obstructive pulmonary diseases; DM: diabetes mellitus; HT: hypertension; F: favipiravir; C: ciclesonide; L/R : lopinavir/ritonavir; mPSL: methylprednisolone

Table 2. Comparative features before tocilizumab administration between well-responding group and rapidly-worsening group

<table>
<thead>
<tr>
<th></th>
<th>Well-responding group (n = 7)</th>
<th>Rapidly-worsening group (n = 4)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>61.6 ± 14.7</td>
<td>61.0 ± 13.3</td>
<td>0.7763</td>
</tr>
<tr>
<td>Comorbidity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>DM (n = 3)</td>
<td>DM (n = 1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HT (n = 2)</td>
<td>HT (n = 2)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>COPD (n = 1)</td>
<td>Obesity (n = 1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NTM (n = 10)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory data</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRP (mg/dL)</td>
<td>9.88 ± 3.88</td>
<td>6.05 ± 2.08</td>
<td>0.0726</td>
</tr>
<tr>
<td>Lymphocytes ( /µL)</td>
<td>834.7 ± 404.6</td>
<td>730.8 ± 196.5</td>
<td>0.5083</td>
</tr>
<tr>
<td>Ferritin (ng/mL)</td>
<td>773.3 ± 546.0</td>
<td>1818.7 ± 1046.0</td>
<td>0.0726</td>
</tr>
<tr>
<td>Ferritin/CRP</td>
<td>83.67 ± 56.68</td>
<td>373.13 ± 346.81</td>
<td>0.0107</td>
</tr>
</tbody>
</table>

DM: diabetes mellitus; HT: hypertension; COPD: chronic obstructive pulmonary diseases; NTM: non-tuberculous mycobacteriosis